

1. [Merck sees deal opportunities as biotech funding gets tighter](#)

– The Hindu

U.S. drugmaker Merck & Co is eager to do deals to bring in promising experimental medicines and believes a recent correction in biotechnology stocks should throw up new opportunities.

“Prices have come back

somewhat. That is a positive thing,” Chief Executive Kenneth Frazier told Reuters in Davos.

1. [Merck sees deal opportunities as biotech funding gets tighter](#) – The Hindu

2. [Fix regulation of clinical trials](#) – Economic Times

3. [Reconsider raising product approval fee: Drug manufacturers to govt](#) – Business Standard

4. [Where Pfizer, Johnson & Johnson, GSK Get Their MBA Talent Injections](#) – Business Because

2. [Fix regulation of clinical trials](#) – Economic Times

Opinion piece on regulations for clinical trials in India

3. [Reconsider raising product approval fee: Drug manufacturers to govt](#) – Business Standard

The Indian Drug Manufacturers Association (IDMA) has asked the Union health ministry to reconsider its proposal on raising fees for product registration, inspection and clinical trials.

“Though we appreciate the need to increase fees for import of bulk drugs to protect the local industry, we are not in favour of any hike for domestic manufacture of bulk drugs or formulations,” said IDMA President S V Veerramani during the association’s 54th annual function in Mumbai on Saturday.

4. [Where Pfizer, Johnson & Johnson, GSK Get Their MBA Talent Injections](#) – Business Because

Story on pharma companies hiring B-school graduates.

As innovation and the chance to improve people’s lives lure b-school students to healthcare, the industry’s biggest players have snapped up MBAs in greater numbers. Companies including Bristol-Myers Squibb, Novartis, GSK, and Pfizer are hiring MBAs. Johnson & Johnson (J&J), Bayer, and Genentech have led the charge.